AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) is scheduled to announce its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.05). The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.22 million. AEterna Zentaris had a negative return on equity of 514.64% and a negative net margin of 1,945.78%. AEterna Zentaris’s revenue was up 153.1% compared to the same quarter last year. On average, analysts expect AEterna Zentaris to post $-1.56 EPS for the current fiscal year and $-0.8 EPS for the next fiscal year.

AEZS has been the subject of several analyst reports. ValuEngine upgraded shares of AEterna Zentaris from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded shares of AEterna Zentaris from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Maxim Group set a $4.00 target price on shares of AEterna Zentaris and gave the company a “buy” rating in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $4.33.

TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at

About AEterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Earnings History for AEterna Zentaris (NASDAQ:AEZS)

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.